Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SK pseudogene 109 (abbreviated RN7SKP109) is classified as a pseudogene of the RN7SK small nuclear RNA gene[3]. Pseudogenes are genomic DNA sequences similar to normal genes but are typically non-functional; they do not produce functional protein or RNA product and are not involved in normal biological processes or drug targeting. RN7SKP109 is considered a non-coding RNA pseudogene and has no known therapeutic or biological role, nor is it implicated as a receptor, enzyme, transporter, or transcription factor[3]. Note: - The functional and biologically relevant gene is RN7SK, which plays a key role in transcription regulation, but RN7SKP109 is a presumed nonfunctional copy (pseudogene), not a true target, and has no known association with human disease, molecular function, or drug interaction[1][3]. - The entries conflating RN7SK with RN7SKP109 are incorrect for therapeutic or mechanistic relevance[1][3]. In summary: RN7SKP109 should not be considered a drug target or biologically functional molecule; it is a pseudogene with no established biological activity, function, or therapeutic implications[3].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RN7SK pseudogene 109 (RN7SKP109).